바이오테크 보도자료
-
- Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion muta...
- 2021년 05월 20일
-
- Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
- Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, and Chime Biologics (“Chime”), a...
- 2021년 05월 18일
-
- PMC Biogenix Announces Price Increase on Armoslip® and Kemamide® Fatty Amides
- PMC Biogenix Inc. announces that effective June 1, 2021 or as contracts permit, prices for Armoslip and Kemamide brand primary and secondary fatty amides and bisamides will increase by $1.00 to $3.00 per kilo for all orders, globally; adjusted for...
- 2021년 05월 17일
-
- Hyundai Bioscience: Niclosamide-based CP-COV03, an Oral Antiviral Drug May Be a Problem Solver for COVID-19
- Hyundai Bioscience (KOSDAQ 048410) announced that Dr. Jin-Ho Choi, a Chief Scientist of its major shareholding bio-tech company CNPharm and Chair Professor at Dankook University, presented the study titled ‘COVID-19 Game Changer Drug - a novel org...
- 2021년 05월 14일
-
- Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
- Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection wil...
- 2021년 05월 14일
-
- Humanigen Reports First Quarter 2021 Financial Results
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial result...
- 2021년 05월 14일
-
- Nuclera Acquires E Ink Digital Microfluidics Unit
- Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into...
- 2021년 05월 14일
-
- Business and Policy Leaders Sign Letter to President Biden Urging U.S. Leadership to Speed Global Vaccination Effort
- A group of 16 international business and policy leaders today published an open letter to U.S. President Joseph R. Biden calling on him to “demonstrate decisive U.S. leadership now” to combat increasingly deadly Covid-19 outbreaks in Latin America...
- 2021년 05월 13일
-
- Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESIDENT AND CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Over the cours...
- 2021년 05월 13일
-
- MagBio Genomics Inc. Develops Automated RNA Purification Chemistry for Mawi iSWAB-RNA v2 on Thermofisher KingFisher™ Flex
- Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofis...
- 2021년 05월 12일
전시회
